Targeting niche factors that promote stemness and plasticity, such as BMI-1 and BCL-3, may be an effective way to target CRC stem cells in primary tumours and prevent reversion of differentiated cells to LGR5+ CSCs. The gene discussed is BCL3; the disease is neoplasm.